Training activity information
Details
Analyse the appropriate genetic testing for haematological malignancy referrals, to include:
- AML
- ALL
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What are the established guidelines and criteria for referring patients with suspected AML or ALL for genetic testing?
- What clinical information is essential to determine if the requested genetic tests are appropriate for the specific clinical scenario?
- What are some common reasons why a genetic test referral for a haematological malignancy might be deemed inappropriate?
- What specific insights do you hope to gain regarding the factors that determine the appropriateness of genetic testing in AML and ALL?
- How will you learn to critically evaluate referral information and align it with relevant testing strategies?
- How will this activity enhance your understanding of the patient pathway and the role of genetics in haematological malignancies?
- Will you review example referral forms and discuss with your training officer the key information to look for when assessing appropriateness?
- What resources (e.g., national guidelines, local testing protocols) will you consult to understand the criteria for genetic testing in AML and ALL?
- What potential challenges might you encounter in determining the appropriateness of a referral (e.g., incomplete clinical information, unusual presentation)? How might you address these?
In action
- How are you currently approaching the analysis of sequencing and cytogenetic data, and what real-time decisions are you making to identify and prioritise genetic alterations critical for diagnosis, prognosis, or treatment stratification?
- What challenges are you encountering—such as interpreting complex mutational profiles, VUS, or integrating data from different modalities—and which aspects require focused reference to guidelines rather than prior experience?
- How are you managing unexpected or unclear findings, for instance by employing alternative analysis strategies or seeking senior advice, to ensure your interpretation remains contextually relevant to the patient’s specific referral?
On action
- What were the key genetic markers that were important to analyse in the AML and ALL cases?
- Were there specific patterns of genetic abnormalities that were associated with particular subtypes or prognoses?
- What challenges did you encounter during the analysis of the genetic data?
- Did you deepen your understanding of the complex genetic landscape of AML and ALL?
- Did you improve your ability to interpret different types of genetic data (e.g., mutations, copy number variations, translocations)?
- How does the analysis of genetic data inform risk stratification and treatment decisions in these malignancies?
- What resources will you use to enhance your skills in analysing genetic data from haematological malignancies?
- How will you ensure accuracy and consistency in your analysis and interpretation?
- What further knowledge do you need to acquire about specific genetic markers and their clinical significance?
Beyond action
- Having now gained more experience in analysing genetic data from haematological malignancies, how does your current analytical approach compare to your initial attempts during this training activity?
- Have you encountered complex cases or challenging data that have refined your analytical skills beyond what you initially learned?
- In your current role, how do you apply the analytical skills developed through this activity when interpreting results from other types of genetic tests?
- Considering the increasing complexity of genomic data in haematological cancers, how will your foundational analytical skills help you to interpret and integrate new types of information in the future?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 3 |
Outcome
Analyse, interpret and report tests for patients referred with sporadic cancer. |